|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.68 USD | +0.98% |
|
-1.28% | -17.69% |
| Apr. 24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
| Apr. 23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
Incyte Corporation provided earnings guidance for 2024. For the year the company expects Jakafi net product revenues of $2,690 million to $2,750 million.
| 1st Jan change | Capi. | |
|---|---|---|
| -17.69% | 11.6B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B | |
| +2.29% | 7.72B |
INCYTE CORPORATION 
